Oren Livnat
Stock Analyst at HC Wainwright & Co.
(2.30)
# 1,444
Out of 4,412 analysts
99
Total ratings
35.51%
Success rate
-0.1%
Average return
Main Sectors:
Top Industries:
16 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ZVRA Zevra Therapeutics | Reiterates: Buy | $15 | $4.52 | +231.86% | 3 | Apr 3, 2024 | |
| JAZZ Jazz Pharmaceuticals | Maintains: Buy | $204 → $200 | $109.46 | +82.72% | 12 | Mar 14, 2024 | |
| XERS Xeris Biopharma Holdings | Maintains: Buy | $5.5 → $6 | $1.75 | +242.86% | 7 | Mar 7, 2024 | |
| AVDL Avadel Pharmaceuticals | Maintains: Buy | $21 → $25 | $17.81 | +40.37% | 9 | Mar 5, 2024 | |
| PCRX Pacira BioSciences | Reiterates: Buy | $57 | $26.33 | +116.48% | 13 | Mar 4, 2024 | |
| ANIP ANI Pharmaceuticals | Maintains: Buy | $73 → $83 | $65.36 | +26.99% | 6 | Mar 4, 2024 | |
| VRCA Verrica Pharmaceuticals | Maintains: Buy | $12 → $13 | $6.87 | +89.23% | 8 | Mar 1, 2024 | |
| TARS Tarsus Pharmaceuticals | Maintains: Buy | $50 → $57 | $32.04 | +77.90% | 7 | Feb 28, 2024 | |
| MNKD MannKind | Reiterates: Buy | $7.5 | $4.23 | +77.30% | 6 | Jan 4, 2024 | |
| CARA Cara Therapeutics | Maintains: Buy | $7 → $2.5 | $0.68 | +265.34% | 8 | Dec 19, 2023 | |
| COLL Collegium Pharmaceutical | Reiterates: Neutral | n/a | $36.42 | - | 4 | Aug 4, 2023 | |
| AGRX Agile Therapeutics | Reiterates: Buy | $12 | $0.40 | +2,900.00% | 8 | Jun 26, 2023 | |
| ACST Acasti Pharma | Initiates: Buy | $14 | $2.81 | +412.46% | 1 | Dec 15, 2022 | |
| SCYX SCYNEXIS | Maintains: Buy | $14 → $8 | $1.54 | +419.48% | 2 | May 13, 2022 | |
| LPCN Lipocine | Maintains: Buy | n/a | $4.80 | - | 3 | Aug 26, 2021 | |
| VYNE VYNE Therapeutics | Maintains: Buy | n/a | $2.50 | - | 2 | May 7, 2021 |
Zevra Therapeutics
Apr 3, 2024
Reiterates: Buy
Price Target: $15
Current: $4.52
Upside: +231.86%
Jazz Pharmaceuticals
Mar 14, 2024
Maintains: Buy
Price Target: $204 → $200
Current: $109.46
Upside: +82.72%
Xeris Biopharma Holdings
Mar 7, 2024
Maintains: Buy
Price Target: $5.5 → $6
Current: $1.75
Upside: +242.86%
Avadel Pharmaceuticals
Mar 5, 2024
Maintains: Buy
Price Target: $21 → $25
Current: $17.81
Upside: +40.37%
Pacira BioSciences
Mar 4, 2024
Reiterates: Buy
Price Target: $57
Current: $26.33
Upside: +116.48%
ANI Pharmaceuticals
Mar 4, 2024
Maintains: Buy
Price Target: $73 → $83
Current: $65.36
Upside: +26.99%
Verrica Pharmaceuticals
Mar 1, 2024
Maintains: Buy
Price Target: $12 → $13
Current: $6.87
Upside: +89.23%
Tarsus Pharmaceuticals
Feb 28, 2024
Maintains: Buy
Price Target: $50 → $57
Current: $32.04
Upside: +77.90%
MannKind
Jan 4, 2024
Reiterates: Buy
Price Target: $7.5
Current: $4.23
Upside: +77.30%
Cara Therapeutics
Dec 19, 2023
Maintains: Buy
Price Target: $7 → $2.5
Current: $0.68
Upside: +265.34%
Collegium Pharmaceutical
Aug 4, 2023
Reiterates: Neutral
Price Target: n/a
Current: $36.42
Upside: -
Agile Therapeutics
Jun 26, 2023
Reiterates: Buy
Price Target: $12
Current: $0.40
Upside: +2,900.00%
Acasti Pharma
Dec 15, 2022
Initiates: Buy
Price Target: $14
Current: $2.81
Upside: +412.46%
SCYNEXIS
May 13, 2022
Maintains: Buy
Price Target: $14 → $8
Current: $1.54
Upside: +419.48%
Lipocine
Aug 26, 2021
Maintains: Buy
Price Target: n/a
Current: $4.80
Upside: -
VYNE Therapeutics
May 7, 2021
Maintains: Buy
Price Target: n/a
Current: $2.50
Upside: -